Astria Therapeutics, Inc.
Astria Therapeutics is dedicated to developing life-changing therapies for allergic and immunologic diseases, guided by patient insights and a commitment to improving patient quality of life. Their mission is to bring hope through innovative treatments, with a focus on patient-centric development and community engagement.
Industries
Nr. of Employees
small (1-50)
Astria Therapeutics, Inc.
22 Boston Wharf Road, 10th Floor, Boston, MA 02210
Patents
Products
Navenibart (STAR-0215)
Investigational monoclonal antibody designed to inhibit plasma kallikrein for prevention of hereditary angioedema attacks; developed as a long-acting preventative with potential dosing every 3 or 6 months.
STAR-0310
Investigational monoclonal antibody OX40 antagonist in development for atopic dermatitis, with preclinical characterization reported and potential to provide less frequent dosing.
Navenibart (STAR-0215)
Investigational monoclonal antibody designed to inhibit plasma kallikrein for prevention of hereditary angioedema attacks; developed as a long-acting preventative with potential dosing every 3 or 6 months.
STAR-0310
Investigational monoclonal antibody OX40 antagonist in development for atopic dermatitis, with preclinical characterization reported and potential to provide less frequent dosing.
Services
Business development service to evaluate and in-license therapeutic candidates across development stages and to engage potential partners.
Design and operation of clinical studies for investigational biologics and management of trial enrollment (investigational drugs accessible only through trial participation).
Business development service to evaluate and in-license therapeutic candidates across development stages and to engage potential partners.
Design and operation of clinical studies for investigational biologics and management of trial enrollment (investigational drugs accessible only through trial participation).
Expertise Areas
- Clinical trial management
- Monoclonal antibody therapeutics
- Rare disease drug development (HAE)
- Dermatology therapeutics (atopic dermatitis)
Key Technologies
- Monoclonal antibody therapeutics
- OX40 antagonism
- Plasma kallikrein inhibition
- Structural biology (protein binding characterization)